One of my pipe dreams I posted on other board this morning::
Company was pretty far along in regards to development of a Kevetrin pill as early as Sping 2017 per a PR at that time and in the PR they said they would have it hammered out by EOY 2017. But, alas, money shortage kept that from being attained.
Now since then what did Dr. Menon have to do in a clinical sense or even in some sort of business sense? Not much, as P and B were pretty much done and finishing up their P2 trials.
Dr. Menon took a pay cut in Mar2018 or so due to his research being done and he now being more of a consultant than a full time employee. Very commendable and just the type of action I would expect of him.
That leaves me to question what he was doing from summer of 2017 to Mar of 2018. If he was simply sitting on his culotso, I would have expected him to cut back his salary much earlier than Mar 2018. And Dr. Menon didn't get to where he is in the world of clinical research by sitting on his ass doing nothing.
Leaves me to believe he was still messing around with some clinical work at HQ. Here is a long shot, maybe he used his salary as a source to further his clinical work (something I wouldn't put past him)and maybe by Mar 2018 he had completed the work on developing the Kevetrin pill.
The pill would still need to be tested for efficacy and safety and to see if it causes a systemic buildup in the body, etc so for this testing IPIX would have to let it sit on the shelf waiting for a further improvement in finances and thus not have to be PRd.
If this got done in Mar, then Dr. Menon had nothing further to address so he took his pay cut and turned to a state of near retirement.
Long shot, but this is the type of thing that could be going on behind the scenes and for which mgt could claim no credit as of yet. But once the first deal is signed and upfront money becomes available, such a development could lead to a very fast track for Kevetrin to become the "wonder drug" of testing as a possible complementary cancer cure with many, many other drugs that currently can't be handled by the body or make better current drug treatments.
Just another of those things that makes one go "hmmmm" in the middle of the night and which could turn things on its ear in a hurry in regards to share price for IPIX.
Combine this news with other PRs in a very short term announcing great Prurisol P2b results and the signing of the term sheet for a a very nice first partnership for B and IPIX is rock and rolling.
Leo has always said he has no love for those that tried to take the company down with false and malicious articles and this type of massive news could really do some serious damage to anybody that has been trying to squash the share price as we have seen over the last couple of years.
Currently just a pipe dream, but nothing I put past mgt in their game plan to further the company and push all 3 drugs to commerciality. Glad I have a nice position should some or all of these opportunities come to pass.
Company was pretty far along in regards to development of a Kevetrin pill as early as Sping 2017 per a PR at that time and in the PR they said they would have it hammered out by EOY 2017. But, alas, money shortage kept that from being attained.
Now since then what did Dr. Menon have to do in a clinical sense or even in some sort of business sense? Not much, as P and B were pretty much done and finishing up their P2 trials.
Dr. Menon took a pay cut in Mar2018 or so due to his research being done and he now being more of a consultant than a full time employee. Very commendable and just the type of action I would expect of him.
That leaves me to question what he was doing from summer of 2017 to Mar of 2018. If he was simply sitting on his culotso, I would have expected him to cut back his salary much earlier than Mar 2018. And Dr. Menon didn't get to where he is in the world of clinical research by sitting on his ass doing nothing.
Leaves me to believe he was still messing around with some clinical work at HQ. Here is a long shot, maybe he used his salary as a source to further his clinical work (something I wouldn't put past him)and maybe by Mar 2018 he had completed the work on developing the Kevetrin pill.
The pill would still need to be tested for efficacy and safety and to see if it causes a systemic buildup in the body, etc so for this testing IPIX would have to let it sit on the shelf waiting for a further improvement in finances and thus not have to be PRd.
If this got done in Mar, then Dr. Menon had nothing further to address so he took his pay cut and turned to a state of near retirement.
Long shot, but this is the type of thing that could be going on behind the scenes and for which mgt could claim no credit as of yet. But once the first deal is signed and upfront money becomes available, such a development could lead to a very fast track for Kevetrin to become the "wonder drug" of testing as a possible complementary cancer cure with many, many other drugs that currently can't be handled by the body or make better current drug treatments.
Just another of those things that makes one go "hmmmm" in the middle of the night and which could turn things on its ear in a hurry in regards to share price for IPIX.
Combine this news with other PRs in a very short term announcing great Prurisol P2b results and the signing of the term sheet for a a very nice first partnership for B and IPIX is rock and rolling.
Leo has always said he has no love for those that tried to take the company down with false and malicious articles and this type of massive news could really do some serious damage to anybody that has been trying to squash the share price as we have seen over the last couple of years.
Currently just a pipe dream, but nothing I put past mgt in their game plan to further the company and push all 3 drugs to commerciality. Glad I have a nice position should some or all of these opportunities come to pass.
6
